The top players in pharma know how to adapt. After M&A, selloffs, cost cuts and therapeutic rejigs, the companies on this list may largely wear the same names, but none entered it looking exactly as they did for last year’s edition. Whether because of buyouts or reorgs or both, companies atop the rankings this year generally have...
Cum sociis natoque penatibus et magnis dis parturient montesmus. Pro vel nibh et elit mollis commodo et nec augueique
Cum sociis natoque penatibus et magnis dis parturient montesmus. Pro vel nibh et elit mollis commodo et nec augueique
With tens of billions of dollars in sales pumping into their coffers each year, the world’s largest publicly traded pharmaceutical companies can be extremely profitable investments for shareholders. But impressive profits––and the welcome return on investment that comes with them––don’t always translate into more innovation or long-term value. Megapharmas spend a lot of money each year investing...
